PharmaTher Holdings Company Description

PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes.

The company’s product pipeline includes KETARX, a ketamine hydrochloride injection for the treatment of Parkinson’s disease, Amyotrophic Lateral Sclerosis, complex regional pain, and anesthesia and procedural sedation.

It develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures.

In addition, the company offers PHARMAPATCH, a microneedle patch technology solution, which includes hydrogel-forming and gelatin methacryloyl delivery system for the treatment of psychedelics and infectious diseases.

Further, it has license agreement with BioRAE, Inc. for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle; and the University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS; as well as holds a patent and know-how license agreement with The Queen’s University of Belfast to develop and commercialize hydrogel-forming microneedle patch delivery technology.

The company was incorporated in 2019 and is headquartered in Toronto, Canada.

PharmaTher Holdings Ltd.

Country	Canada
Founded	2019
Industry	Biotechnology
Sector	Healthcare
CEO	Fabio Chianelli

Contact Details

Address: 82 Richmond Street East Toronto, Ontario M5C 1P1 Canada
Phone	888-846-3171
Website	pharmather.com

Stock Details

Ticker Symbol	PHRM
Exchange	Canadian Securities Exchange
Fiscal Year	June - May
Reporting Currency	CAD
ISIN Number	CA71716H1082
SIC Code	2834

Key Executives

Name	Position
Fabio Chianelli	Founder, Chairman and Chief Executive Officer
Carmelo Marrelli ACIS, B.Comm., C.A., C.P.A., CGA, CPA	Chief Financial Officer
Andrew Todd	Corporate Secretary